XML 39 R20.htm IDEA: XBRL DOCUMENT v3.25.0.1
Revenue
12 Months Ended
Dec. 31, 2024
Revenue.  
Revenue

Note 14.  Revenue

We derive our revenue from the sale and rental of our products to our customers in the United States. The following table presents our revenue, inclusive of sales and rental revenue, disaggregated by product:

Year Ended

December 31,

(In thousands)

2024

2023

2022

Revenue

Lymphedema products

$

259,361

$

241,721

$

212,266

Airway clearance products

33,623

32,702

34,519

Total

$

292,984

$

274,423

$

246,785

Percentage of total revenue

Lymphedema products

 

89%

 

88%

 

86%

Airway clearance products

11%

12%

14%

Total

 

100%

 

100%

 

100%

Our revenue by channel, inclusive of sales and rental revenue, for the years ended December 31, 2024, 2023 and 2022, are summarized in the following table:

Year Ended

December 31,

(In thousands)

2024

2023

2022

Private insurers and other payers

$

175,432

$

148,901

$

139,087

Veterans Administration

30,890

27,003

25,507

Medicare

53,039

65,817

47,672

Durable medical equipment distributors

33,623

32,702

34,519

Total

$

292,984

$

274,423

$

246,785

Our rental revenue is derived from rent-to-purchase arrangements that typically range from three to ten months. As title transfers to the patient, with whom we have the contract, upon the termination of the lease term and because collectability is probable, under ASC 842, these are recognized as sales-type leases. Each rental agreement contains two components, the controller and related garments, both of which are interdependent and recognized as one lease component.

The revenue and associated cost of revenue of sales-type leases are recognized on the lease commencement date and a net investment in leases is recorded on the Consolidated Balance Sheet. We bill the patients’ insurance payers monthly over the duration of the rental term. We record the net investment in leases and recognize revenue upon commencement of the lease in the amount of the expected consideration to be received through the monthly payments. Similar to our sales revenue, the transaction price is impacted by multiple factors, including the terms and conditions contracted by various third party payers. As the rental contract resides with the patients, we have elected the portfolio approach, at the payer level, to determine the expected consideration, which considers the impact of early terminations. While the contract is with the patient, in certain circumstances, the third party payer elects an initial rental period with an option to extend. We assess the likelihood of extending the lease at the onset of the lease to determine if the option is reasonably certain to be exercised. As the lease is short-term in nature, we anticipate collection of substantially all of the net investment within the first year of the lease agreement. Completion of these payments represents the fair market value of the equipment, and as such, interest income is not applicable.

Rental revenue for the years ended December 31, 2024, 2023 and 2022, was primarily from private insurers. Sales-type lease revenue and the associated cost of revenue for the years ended December 31, 2024, 2023 and 2022, was:

Year Ended December 31,

(In thousands)

2024

2023

2022

Sales-type lease revenue

$

36,972

$

34,930

$

35,440

Cost of sales-type lease revenue

 

11,481

 

12,577

 

11,190

Gross profit

$

25,491

$

22,353

$

24,250